Abstract:Significant enthusiasm currently exists for new immunotherapeutic strategies: blocking the interaction between programmed death-1 receptor on T-cells and programmed death-ligand 1 on tumor cells to boost immune system stimulation to fight cancer. Immunomodulation with the antiprogrammed death-1/programmed death-ligand 1 monoclonal antibodies has shown to mediate tumor shrinkage and extend overall survival from several pivotal phase I/II studies in melanoma, renal cell carcinoma, and non-small cell lung cancer. This has prompted multiple large ongoing phase III trials with the expectation for fast-track FDA approvals to satisfy unmet medical needs. Compounds targeting the programmed death-1 pathway that are in clinical trials fall into two major categories, namely antiprogrammed death-1 antibodies: Nivolumab, MK-3475, and pidilizumab; and antiprogrammed death-ligand 1 antibodies: MPDL3280A, BMS-936559, MEDI4736, and MSB0010718C. We reviewed the clinical efficacy and safety of each compound based upon major registered clinical trials and published clinical data. Overall, response rate of more than 20% is consistently seen across all these trials, with maximal response of approximately 50% achieved by certain single antiprogrammed death-1 agents or when used in combination with cytotoxic T-lymphocyte antigen-4 blockade. The responses seen are early, durable, and have continued after treatment discontinuation. Immune-related adverse events are the most common side effects seen in these clinical trials. Overall, the skin and gastrointestinal tract are the most common organ systems affected by these compounds while hepatic, endocrine, and neurologic events are less frequent. These side effects are low grade, manageable, and typically resolve within a relatively short time frame with a predictable resolution pattern given proper management. We therefore propose detailed guidelines for management of major immune-related adverse events that are anticipated with antiprogrammed death-1/programmed death-ligand 1 therapies based on general experience with other monoclonal antibodies and the established management algorithms for immune-related adverse events for cytotoxic T-lymphocyte antigen-4 blockade with ipilimumab. We anticipate that the antiprogrammed death-1 strategy will become a viable and crucial clinical strategy for cancer therapy.

The current progress of PD-1 / PD-L1 mAb applications in melanoma immunotherapy

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (neo) Adjuvant Therapy for Malignant Melanoma

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Immunotherapy of Human Melanoma: Past, Present, Future

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update

The safety of anti PD-1 therapeutics for the treatment of melanoma

Deciphering and Overcoming Anti-PD-1 Resistance in Melanoma: A Comprehensive Review of Mechanisms, Biomarker Developments, and Therapeutic Strategies.

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Research Progress in PD-1/PD-L1 antibodies treating human cancers

PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance

Recent advances of immune checkpoint inhibitors for treatment of melanoma

Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma

Companion Diagnostics and Predictive Biomarkers for PD-1/PD-L1 Immune Checkpoint Inhibitors Therapy in Malignant Melanoma

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations